Vertex Pharmaceuticals
VRTX
Market cap $101B

388.94 USD

-6.18

1.56%

At close Aug 25, 4:00 PM EDT

After hours

390.35

+1.41

0.36%

1 day

-1.56%

5 days

-0.18%

1 month

-17.19%

3 months

-12.79%

6 months

-19.03%

Year to date

-4.15%

1 year

-19.41%

5 years

42.81%

10 years

220.99%

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 6,100

Healthcare Biotechnology

0

Funds holding %

of 7,429 funds

0

Analysts bullish %

of 14 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

92% more call options, than puts

Call options by funds: $716M | Put options by funds: $374M

1.47% more ownership

Funds ownership: 91.96% [Q1] → 93.42% (+1.47%) [Q2]

1% less repeat investments, than reductions

Existing positions increased: 596 | Existing positions reduced: 602

4% less funds holding

Funds holding: 1,592 [Q1] → 1,521 (-71) [Q2]

7% less capital invested

Capital invested by funds: $115B [Q1] → $107B (-$7.71B) [Q2]

18% less first-time investments, than exits

New positions opened: 116 | Existing positions closed: 142

46% less funds holding in top 10

Funds holding in top 10: 26 [Q1] → 14 (-12) [Q2]

See Fund Rankings

Research analyst outlook

14 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$405

4%

upside

Avg. target

$483

24%

upside

High target

$553

42%

upside

14 analyst ratings

9 positive

64%

5 neutral

36%

0 negative

0%

Canaccord Genuity Whitney Ijem	6%upside $411	Hold Maintained	6 Aug 2025
Guggenheim Debjit Chattopadhyay	40%upside $546	Buy Maintained	6 Aug 2025
Wells Fargo Mohit Bansal	18%upside $460	Overweight Upgraded	6 Aug 2025
Truist Securities Joon Lee	26%upside $490	Buy Maintained	5 Aug 2025
Scotiabank Greg Harrison	13%upside $438	Sector Perform Maintained	5 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 42 articles about VRTX published over the past 30 days

The Motley Fool

This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy?

Vertex Pharmaceuticals (VRTX -0.45%) is usually a market-beater, but it hasn't been so over the past year. The company's shares are down 18% over the trailing-12-month period due to a combination of headwinds.

This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy?

The Motley Fool

2 Beaten-Down Stocks With Incredible Upside Potential

What goes up can come down. Most investors have experienced this first-hand with stocks in their portfolio.

2 Beaten-Down Stocks With Incredible Upside Potential

Vertex to Participate in Upcoming September Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 11:00 a.m. ET. Reshma Kewalramani, President and Chief Executive Officer, and Duncan McKechnie, Executive Vice P.

Vertex to Participate in Upcoming September Investor Conferences

The Motley Fool

What's Wrong With Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals (VRTX 0.17%) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process.

What's Wrong With Vertex Pharmaceuticals Stock?

Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More

This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear growth catalysts for 2025 and beyond. Caution is urged on popular income-focused ETFs like SPYI and ULTY, as structural flaws and capped upside may limit long-term wealth compounding.

Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More

The Motley Fool

3 Fantastic Growth Stocks to Buy in August

We're well into the home stretch of 2025. August is more than halfway over.

3 Fantastic Growth Stocks to Buy in August

The Motley Fool

Is This Beaten-Down Stock a Buy on the Dip?

Even well-established drugmakers can lose significant market value overnight following a setback. That's what recently happened to Vertex Pharmaceuticals (VRTX 0.47%).

Is This Beaten-Down Stock a Buy on the Dip?

The Motley Fool

2 Growth Stocks That Are No-Brainer Buys Right Now

Over the past five years, the stock market has endured a pandemic and the economic issues that followed, along with inflationary pressures, geopolitical tensions, trade wars, and other macroeconomic challenges. Despite all that, equities have performed well.

2 Growth Stocks That Are No-Brainer Buys Right Now

Zacks Investment Research

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

A 20% drop in Vertex Pharmaceuticals' stock price since I wrote last month was the impetus to make a re-assessment. But the rating has remained unchanged at Hold. This is despite significantly improved Q2 2025 results, seen in both revenue and non-GAAP earnings' growth, with revenues supported by the likes of Alyftrek and Journavx,. However, an unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led to a price plunge.

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

See News Rankings

Charts implemented using Lightweight Charts™